Catecholamine Dosing and Survival in Adult Intensive Care Unit Patients
Marc Kastrup
Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité-University Medicine Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
Search for more papers by this authorJan Braun
Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité-University Medicine Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
Search for more papers by this authorMagnus Kaffarnik
Department of General, Visceral, and Transplantation Surgery, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Berlin, Germany
Search for more papers by this authorVera von Dossow-Hanfstingl
Klinikum Großhadern, LMU München, Marchioninistrasse 15, 81377 Munich, Germany
Search for more papers by this authorRobert Ahlborn
IT-Department Charité-University Medicine-Berlin, Berlin, Germany
Search for more papers by this authorKlaus-D Wernecke
Institute for Biometrics and Clinical Epidemiology, Charité-University Medicine Berlin and Sostana GmbH, Berlin, Germany
Search for more papers by this authorCorresponding Author
Claudia Spies
Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité-University Medicine Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
claudia.spies@charite.deSearch for more papers by this authorMarc Kastrup
Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité-University Medicine Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
Search for more papers by this authorJan Braun
Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité-University Medicine Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
Search for more papers by this authorMagnus Kaffarnik
Department of General, Visceral, and Transplantation Surgery, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Berlin, Germany
Search for more papers by this authorVera von Dossow-Hanfstingl
Klinikum Großhadern, LMU München, Marchioninistrasse 15, 81377 Munich, Germany
Search for more papers by this authorRobert Ahlborn
IT-Department Charité-University Medicine-Berlin, Berlin, Germany
Search for more papers by this authorKlaus-D Wernecke
Institute for Biometrics and Clinical Epidemiology, Charité-University Medicine Berlin and Sostana GmbH, Berlin, Germany
Search for more papers by this authorCorresponding Author
Claudia Spies
Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité-University Medicine Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
claudia.spies@charite.deSearch for more papers by this authorAbstract
Background
Volume management and vasopressor support remain the gold standard of critical care for patients with shock. However, prolonged therapy with catecholamines in high doses is associated with a negative patient outcome. The aim of the present study was to analyze the administered levels of catecholamines over time with respect to survival, and to identify a cut-off to allow a prediction of survival.
Methods
Consecutively, 9,108 adult patients during 22 months were evaluated. This group included 1,543 patients treated with epinephrine and/or norepinephrine with any dose at any time. Time and dosages of the applied drugs, the sequential organ failure assessment and acute and chronic health evalutation II scores on admission and daily, the length of intensive care unit stay, and the outcomes were recorded.
Results
The non-survivors received higher doses of norepinephrine and epinephrine than the survivors (p < 0.001). The receiver operator characteristic curve for the area under the curve with non-survival as the classifier revealed a cut-off level of 294.33 μg/kg for norepinephrine with a sensitivity of 74.73 % and a specificity of 70.48 % and a cut-off for epinephrine of 70.36 μg/kg with a sensitivity of 83.87 % and a specificity of 72.79 %. Dose-dependent time curves using these cut-off values were calculated.
Conclusions
Survival of patients with prolonged therapy with norepinephrine and epinephrine above the evaluated thresholds is poor, whereas short-term application of high-dose catecholamines is not associated with poor outcome. Therefore, it remains for the individual clinician, patients, and their surrogates to decide whether the use of high doses of vasopressors is appropriate in view of the low probability of survival.
References
- 1AfessaB, KeeganMT, HubmayrRD et al. Evaluating the performance of an institution using an intensive care unit benchmark. Mayo Clin Proc (2005) 80: 174–1801570477110.4065/80.2.174
- 2DellingerRP, LevyMM, CarletJM et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med (2008) 34: 17–601805808510.1007/s00134-007-0934-2
- 3Reinhart K, Brunkhorst FM, Bone H-G et al. (2010) Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2 k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci 8: Doc14
- 4KnausWA, WagnerDP, ZimmermanJE et al. Variations in mortality and length of stay in intensive care units. Ann Intern Med (1993) 118: 753–7618470850
- 5ShiramizoSC, MarraAR, DuraoMS et al. Decreasing mortality in severe sepsis and septic shock patients by implementing a sepsis bundle in a hospital setting. PloS One (2011) 6: e267902207319310.1371/journal.pone.0026790
- 6VarpulaM, TallgrenM, SaukkonenK et al. Hemodynamic variables related to outcome in septic shock. Intensive Care Med (2005) 31: 1066–10711597352010.1007/s00134-005-2688-z
- 7LevyB, BollaertPE, CharpentierC et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med (1997) 23: 282–287908323010.1007/s001340050329
- 8ZhouSX, QiuHB, HuangYZ et al. Effects of norepinephrine, epinephrine, and norepinephrine-dobutamine on systemic and gastric mucosal oxygenation in septic shock. Acta Pharmacol Sin (2002) 23: 654–65812100762
- 9AsfarP, De BackerD, Meier-HellmannA et al. Clinical review: influence of vasoactive and other therapies on intestinal and hepatic circulations in patients with septic shock. Crit Care (2004) 8: 170–1791515323510.1186/cc2418
- 10AnnaneD, VignonP, RenaultA et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet (2007) 370: 676–6841772001910.1016/S0140-6736(07)61344-0
- 11De BackerD, CreteurJ, SilvaE et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best?. Crit Care Med (2003) 31: 1659–16671279440110.1097/01.CCM.0000063045.77339.B6
- 12Mullner M, Urbanek B, Havel C et al. (2004) Vasopressors for shock. Cochrane Database Syst Rev 2004: CD003709
- 13VincentJL Forgoing life support in western European intensive care units: the results of an ethical questionnaire. Crit Care Med (1999) 27: 1626–16331047077510.1097/00003246-199908000-00042
- 14LamontagneF, CookDJ, AdhikariNK et al. Vasopressor administration and sepsis: a survey of Canadian intensivists. J Crit Care (2011) 26(532): e1–e721454040
- 15BenbenishtyJ, WeissmanC, SprungCL et al. Characteristics of patients receiving vasopressors. Heart Lung (2011) 40: 247–2522063059410.1016/j.hrtlng.2010.04.007
- 16CarletJ, ThijsLG, AntonelliM et al. Challenges in end-of-life care in the ICU. Statement of the 5th International Consensus Conference in Critical Care: Brussels, Belgium, April 2003. Intensive Care Med (2004) 30: 770–7841509808710.1007/s00134-004-2241-5
- 17HamannJ, NeunerB, KasperJ et al. Participation preferences of patients with acute and chronic conditions. Health Expect (2007) 10: 358–3631798607210.1111/j.1369-7625.2007.00458.x
- 18MurrayE, PollackL, WhiteM et al. Clinical decision-making: patients’ preferences and experiences. Patient Educ Couns (2007) 65: 189–1961695674210.1016/j.pec.2006.07.007
- 19KoxWJ Check-up anästhesiologie: standards anästhesie-intensivmedizin-schmerztherapie-notfallmedizin (2005) HeidelbergSpringer10.1007/b138772Google Scholar
- 20HernandezG, BruhnA, RomeroC et al. Implementation of a norepinephrine-based protocol for management of septic shock: a pilot feasibility study. J Tauma (2006) 60: 77–8110.1097/01.ta.0000202062.49814.f4
- 21KernH, SchröderT, KaulfussM et al. Enoximone in contrast to dobutamine improves hepatosplanchnic function in fluid-optimized septic shock patients. Crit Care Med (2001) 29: 1519–15251150511910.1097/00003246-200108000-00004
- 22MicekST, ShahP, HollandsJM et al. Addition of vasopressin to norepinephrine as independent predictor of mortality in patients with refractory septic shock: an observational study. Surg Infect (Larchmt) (2007) 8: 189–20010.1089/sur.2006.003
- 23KatsaragakisS, KapralouA, TheodorouD et al. Refractory septic shock: efficacy and safety of very high doses of norepinephrine. Methods Find Exp Clin Pharmacol (2006) 28: 307–3131684544810.1358/mf.2006.28.5.990203
- 24ChouCY, YehHC, ChenW et al. Norepinephrine and hospital mortality in critically ill patients undergoing continuous renal replacement therapy. Artif Organs (2011) 35: E11–E1721314834
- 25JenkinsCR, GomersallCD, LeungP et al. Outcome of patients receiving high dose vasopressor therapy: a retrospective cohort study. Anaesth Intensive Care (2009) 37: 286–28919400494
- 26AbboudI, LerolleN, UrienS et al. Pharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status. Crit Care (2009) 13: R1201962216910.1186/cc7972
- 27BeloeilH, MazoitJX, BenhamouD et al. Norepinephrine kinetics and dynamics in septic shock and trauma patients. Br J Anaesth (2005) 95: 782–7881622733410.1093/bja/aei259
- 28AbidO, AkcaS, Haji-MichaelP et al. Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure. Crit Care Med (2000) 28: 947–9491080926410.1097/00003246-200004000-00006
- 29SprungCL, CohenSL, SjokvistP et al. End-of-life practices in European intensive care units: the Ethicus Study. JAMA (2003) 290: 790–7971291543210.1001/jama.290.6.790
- 30BellomoR, WanL, MayC Vasoactive drugs and acute kidney injury. Crit Care Med (2008) 36: S179–S1861838219110.1097/CCM.0b013e318169167f
- 31SchneidermanLJ, CapronAM How can hospital futility policies contribute to establishing standards of practice?. Cambridge Q Healthc Ethics (2000) 9: 524–53110.1017/S0963180100904110
- 32TruogRD, CampbellML, CurtisJR et al. Recommendations for end-of-life care in the intensive care unit: a consensus statement by the American college [corrected] of Critical Care Medicine. Crit Care Med (2008) 36: 953–9631843128510.1097/CCM.0B013E3181659096
- 33PrendergastTJ, LuceJM Increasing incidence of withholding and withdrawal of life support from the critically ill. Am J Respir Crit Care Med (1997) 155: 15–209001282
- 34VincentJL Cultural differences in end-of-life care. Crit Care Med (2001) 29: N52–N551122857410.1097/00003246-200102001-00010
- 35RussellJA, WalleyKR, SingerJ et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med (2008) 358: 8771830526510.1056/NEJMoa067373
- 36DunserMW, RuokonenE, PettilaV et al. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care (2009) 13: R1811991710610.1186/cc8167
Recommended
Metrics
Details
© 2013 The Author(s) under exclusive licence to Société Internationale de Chirurgie
Keywords
Publication History
- 31 January 2013
- 31 January 2013
